Baricitinib, as a JAK1/JAK2 inhibitor, modulates cytokines associated with both acute (JAK1: IL-4, -6, -10, -13, -31, IFN-γ / JAK2: IL-5, -6, -23, -31, IFN-γ, GMCSF) and chronic (JAK2: IL-23) AD lesions.16 Here, JAK1 is linked to Alzheimer disease.